EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Closing the Gap: Advances and Barriers on Candida Vaccines Development in the Last Decade

Julie Krier, Jontana Allkja iD, Alexandra Mónica Bastos Viana da Costa iD, Francisco A M Silva iD, Célia Fortuna Rodrigues iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27198490 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Julie Krier und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University Institute of Health Sciences (IUCS-CESPU), 4585-116 Gandra, Portugal. Hauptthemen laut MEDLINE: Fungal Vaccines, Vaccine Development, Candida, Candidiasis. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e Tecnologia, FCT—Fundação para a Ciência e Tecnologia, Research Unit on Applied Molecular Biosciences—UCIBIO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Invasive Candidiasis (IC) remains a critical threat to global health. Primarily caused by Candida albicans, it is increasingly driven by emerging Non-Candida albicans Candida Species (NCACs). IC typically arises from the overgrowth of commensal Candida species in immunocompromised hosts. IC accounts for an estimated 250,000–700,000 cases annually worldwide, with mortality rates between 40 and 55%, and contributes to more than 1.5 million annual deaths. Despite progress in healthcare systems, intensive care, and microbiological techniques, mortality rates remain largely unchanged. Triazole resistance is already widespread, and echinocandin resistance, while still low, is steadily climbing. The emergence of multidrug-resistant Candida auris, the growing immunocompromised population, and the absence of any antifungal vaccine collectively define this scenario as a therapeutic impasse. Given these challenges, there is an urgent need to synthesize current vaccine research to identify robust candidates and address lingering translational bottlenecks. This structured narrative review evaluates the advances and barriers in Candida spp. vaccine development over the past decade (2015–2025), structured around epidemiology and resistance; immunological framework underpinning vaccine design; antigenic targets and delivery platforms; and preclinical and clinical evidence. Key milestones included the Phase II clinical validation of NDV-3A, the first successful large-scale human trial of a fungal vaccine; the standardization of the A/J mouse model for C. auris; the emergence of multi-epitope computational platforms with >94% HLA population coverage; and cross-kingdom protection paradigms. Major obstacles included commensal-to-pathogen duality of Candida, immunocompromised host paradox, antigenic plasticity, and chronic underinvestment. Converging next-generation vaccine strategies are beginning to bridge the gap between bench discovery and clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fungal VaccinesVaccine DevelopmentCandidaCandidiasisCandidiasis, InvasiveHumansAnimals

Stichwörter der Autor:innen

Candida aurisCandida spp.NDV-3ARVVCantifungal vaccineinvasive candidiasismultidrug resistancereverse vaccinologytrained immunity

Substanzen

Fungal Vaccines

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University Institute of Health Sciences (IUCS-CESPU), 4585-116 Gandra, Portugal.
  • Open Innovation Hub for Antimicrobial Surfaces, Surface Science Research Centre, School of Physical Sciences, University of Liverpool, Liverpool L69 3BX, UK.
  • Associate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, 4585-116 Gandra, Portugal.
  • UCIBIO-Applied Molecular Biosciences Unit, Translational Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal.
  • LEPABE/ALiCE-Laboratory for Process Engineering, Environment, Biotechnology and Energy and Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto…

ORCID-Profile: Jontana Allkja, Alexandra Mónica Bastos Viana da Costa, Francisco A M Silva, Célia Fortuna Rodrigues

Förderung

  • Fundação para a Ciência e Tecnologia
  • FCT—Fundação para a Ciência e Tecnologia
  • Research Unit on Applied Molecular Biosciences—UCIBIO

Zitieren

APA

Krier, J., Allkja, J., Viana da Costa, A. M. B., Silva, F. A. M., & Rodrigues, C. F. (2026). Closing the Gap: Advances and Barriers on Candida Vaccines Development in the Last Decade. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27198490

Vancouver

Krier J, Allkja J, Viana da Costa AMB, Silva FAM, Rodrigues CF. Closing the Gap: Advances and Barriers on Candida Vaccines Development in the Last Decade. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27198490

BibTeX
@article{Krier2026,
  author = {Krier, Julie and Allkja, Jontana and Viana da Costa, Alexandra Mónica Bastos and Silva, Francisco A M and Rodrigues, Célia Fortuna},
  title = {Closing the Gap: Advances and Barriers on Candida Vaccines Development in the Last Decade},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27198490}
}
Kostenlos starten →